VioQuest Pharmaceuticals (VOQP) Stock Price, News & Analysis

Company Overview

VioQuest Pharmaceuticals, Inc. was a biopharmaceutical company focused on the development of treatments for cancer and other serious diseases. The company’s activities centered on advancing investigational therapies rather than marketing a broad portfolio of established commercial products.

VioQuest’s development pipeline included VQD-002, an investigational oncology compound based on sodium stibogluconate. The company evaluated this candidate for its potential use in cancer treatment, although publicly available information about its development and commercial status is limited.

VioQuest Pharmaceuticals was primarily associated with the U.S. biotechnology and pharmaceutical market. Detailed, current information about its operations, leadership, geographic reach and product portfolio is not readily available from reliable public sources.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 10/29/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:VOQP
• CIK: N/A
• Web: www.vioquestpharm.com
• Phone: (612) 220-3237
• Fax: N/A
• Employees: 3
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A